Patents by Inventor Toshio Imai
Toshio Imai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160085750Abstract: A storage apparatus includes a storage unit configured to include a plurality of tiers, a group management unit configured to manage files stored in any of the tiers in the storage unit by dividing the files into a plurality of groups, a movement target selection unit configured to select a group, out of the groups, which satisfies a tier movement condition as a movement target of the tier, and a file movement unit configured to move a subordinate file belonging to the group selected by the movement target selection unit, from a tier in which the subordinate file is stored to another tier.Type: ApplicationFiled: August 11, 2015Publication date: March 24, 2016Applicant: FUJITSU LIMITEDInventors: Suijin TAKETA, Yasuhiro Onda, TOSHIO IMAI
-
Publication number: 20160046707Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: ApplicationFiled: August 3, 2015Publication date: February 18, 2016Inventors: Toshio Imai, James Bradford Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Patent number: 9200066Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies.Type: GrantFiled: March 15, 2013Date of Patent: December 1, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Keiko Yamaguchi, Toshio Imai, Kenzo Muramoto
-
Patent number: 9175073Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies.Type: GrantFiled: March 15, 2013Date of Patent: November 3, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Keiko Yamaguchi, Toshio Imai, Kenzo Muramoto
-
Publication number: 20150299654Abstract: The present invention relates to polynucleotide probes and antibodies for detecting Lrp4/Corin dopaminergic neuron progenitor cell markers, which enable the efficient separation of dopaminergic neuron progenitor cells; and methods for selecting the progenitor cells by the use thereof.Type: ApplicationFiled: May 4, 2015Publication date: October 22, 2015Inventors: Yoshimasa Sakamoto, Yuichi Ono, Toshio Imai, Yasuko Nakagawa
-
Patent number: 9133273Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: GrantFiled: June 21, 2013Date of Patent: September 15, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Toshio Imai, James Bradford Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Publication number: 20150056201Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies.Type: ApplicationFiled: October 30, 2014Publication date: February 26, 2015Inventors: Keiko Yamaguchi, Toshio Imai, Kenzo Muramoto
-
Patent number: 8932592Abstract: The present invention features compositions and methods related to humanized antibodies and FKN-binding fragments thereof that bind fractalkine.Type: GrantFiled: October 28, 2010Date of Patent: January 13, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Miyuki Nishimura, Yoshimasa Sakamoto, Tetsu Kawano, Toshio Imai
-
Publication number: 20140287220Abstract: A building board includes an inorganic board having a surface covered by an insulating coating film containing a coating film forming material and organic hollow particles, wherein the organic hollow particles have an average particle size in the range of 5 to 50 ?m and an average hollow ratio of 80% or more, and the insulating coating film contains 0 01 to 5.0 parts by mass of the organic hollow particles per 100 parts by mass of solid content thereof, and has an average thickness of 5 to 500 ?m. The method for producing a building board includes: applying, onto a surface of an inorganic board, an insulating coating material containing a coating film forming material and organic hollow particles; and drying the insulating coating material to form an insulating coating film.Type: ApplicationFiled: December 9, 2013Publication date: September 25, 2014Applicant: Nichiha CorporationInventors: Toshio IMAI, Hiroaki YAMAMOTO
-
Publication number: 20140193421Abstract: An object of the present invention is to provide a monoclonal antibody binding to human XCR1, wherein the antibody binds to linear or discontinuous epitopes which comprise at least three amino acids selected from the group consisting of the 8th, 11th, 12th, 13th, 14th, 16th, 17th, 22nd, 23rd, 176th, and 177th amino acids in the amino acid sequence of SEQ ID NO: 91.Type: ApplicationFiled: August 30, 2012Publication date: July 10, 2014Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Yoshimasa Sakamoto, Miyuki Nishimura, Tetsu Kawano, Yukihisa Sawa, Toshio Imai
-
Publication number: 20140120342Abstract: A building board includes a base material, an insulating coating film for covering a surface of the base material, and a transparent clear coating film for covering the insulating coating film. The insulating coating film contains a coating film forming material, organic hollow particles, and a water-soluble solvent. The method for producing the building board includes a step of forming an insulating coating film in which an insulating paint is applied to a surface of the base material and then dried to form the insulating coating film, and a step of forming a clear coating film in which a clear paint is applied to a surface of the insulating coating film and then dried to form the clear coating film. The insulating paint contains a coating film forming material, organic hollow particles, and a water-soluble solvent.Type: ApplicationFiled: October 30, 2013Publication date: May 1, 2014Applicant: Nichiha CorporationInventors: Toshio IMAI, Hiroaki YAMAMOTO
-
Publication number: 20140045215Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: ApplicationFiled: June 21, 2013Publication date: February 13, 2014Inventors: Toshio Imai, Brad Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Patent number: 8568870Abstract: A building material and a method for coating a substrate for the building material with a coating film having a variety of functions relating to an environment such as mildew resistance, deodorization, antibacterial activity and air purification in addition to the anti-staining effect by having an excellent hydrophilicity. The method for coating the substrate for a building material comprises the steps of; coating a coating material comprising a hydrophilic polymer and a photocatalyst on the substrate, and drying the coating material to form a coating film containing the photocatalyst, wherein the hydrophilic polymer is at least one selected from the group consisting of methyl silicate, liquid glass, colloidal silica, poly(meth)acrylate, and polytetrafluoroethylene graft-polymerized with sulfonic acid, and the photocatalyst is at least one selected from the group consisting of titanium oxide coated with zeolite, titanium oxide coated silica and titanium oxide coated with apatite.Type: GrantFiled: November 21, 2008Date of Patent: October 29, 2013Assignee: Nichiha CorporationInventors: Toshio Imai, Toshifumi Takahashi, Yoshinori Hibino
-
Publication number: 20130230523Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies.Type: ApplicationFiled: March 15, 2013Publication date: September 5, 2013Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Keiko Yamaguchi, Toshio Imai, Kenzo Muramoto
-
Publication number: 20130231466Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies.Type: ApplicationFiled: March 15, 2013Publication date: September 5, 2013Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Keiko Yamaguchi, Toshio Imai, Kenzo Muramoto
-
Patent number: 8518401Abstract: A therapeutic agent for an inflammatory disease comprising an antibody or a CX3CR1 antagonist that inhibits an interaction of fractalkine and CX3CR1 is provided.Type: GrantFiled: October 31, 2005Date of Patent: August 27, 2013Assignee: Eisai R&D Management Co., Ltd.Inventors: Yoshikazu Kuboi, Toshio Imai, Miyuki Nishimura, Keiko Mizuno
-
Patent number: 8491901Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: GrantFiled: November 18, 2011Date of Patent: July 23, 2013Inventors: Toshio Imai, Brad Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Publication number: 20120213799Abstract: The present invention features compositions and methods related to humanized antibodies and FKN-binding fragments thereof that bind fractalkine.Type: ApplicationFiled: October 28, 2010Publication date: August 23, 2012Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Miyuki Nishimura, Yoshimasa Sakamoto, Tetsu Kawano, Toshio Imai
-
Publication number: 20120148592Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: ApplicationFiled: November 18, 2011Publication date: June 14, 2012Inventors: Toshio Imai, Brad Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Publication number: 20110294986Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies.Type: ApplicationFiled: August 11, 2011Publication date: December 1, 2011Applicant: Eisai R&D Management Co., Ltd.Inventors: Keiko Yamaguchi, Toshio Imai, Kenzo Muramoto